Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 17/20 | 0.51 |
| ▸ | RARG | P13631 | 7/20 | 0.51 |
| ▸ | RARB | P10826 | 6/20 | 0.51 |
| ▸ | RARA | P10276 | 4/20 | 0.50 |
| ▸ | RXRB | P28702 | 7/20 | 0.48 |
| ▸ | RXRG | P48443 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6880773 | 0.88 | RARG (0.49) | RXRARARGRARBRARARXRB | |
| SCHEMBL6879444 | 0.86 | RXRA (0.51) | RXRARARGRARBRARARXRB | |
| SCHEMBL6880758 | 0.84 | RXRA (0.59) | RXRARARGRARBRARARXRB | |
| SCHEMBL6874354 | 0.83 | RXRA (0.48) | RXRARARGRARBRARARXRB | |
| SCHEMBL6870964 | 0.81 | RXRA (0.51) | RXRARARGRARBRARARXRB | |
| SCHEMBL6032308 | 0.77 | RXRA (0.52) | RXRARARGRARBRARARXRB | |
| SCHEMBL6874711 | 0.77 | RARG (0.50) | RXRARARGRARBRARARXRB | |
| SCHEMBL6879439 | 0.76 | RXRA (0.45) | RXRARARGRARBRARARXRB | |
| SCHEMBL6879427 | 0.76 | RXRA (0.73) | RXRARARGRARBRARACYP26A1 | |
| SCHEMBL5364751 | 0.75 | RARB (0.68) | RXRARARGRARBRARARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030135053-A1 | For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics | BERNARDON JEAN-MICHEL | 2003-07-17 | — | — | US | claimed |
| US-20030060491-A1 | Bicyclic aromatic compounds | BERNARDON JEAN-MICHEL (FR) | 2003-03-27 | — | — | US | claimed |
| US-6515021-B1 | Bicyclic aromatic compounds | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2003-02-04 | — | — | US | claimed |
| US-6147255-A | TOPICAL AND SYSTEMIC TREATMENT OF DERMATOLOGICAL COMPLAINTS ASSOCIATED WITH KERATINIZATION DISORDER WHICH HAS EFFECT ON DIFFERENTIATION AND ON PROLIFERATION | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-11-14 | — | — | US | claimed |
| US-6825360-B1 | Bicyclic aromatic compounds | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-11-30 | — | — | US | disclosed |
| US-20030135053-A1 | For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics | BERNARDON JEAN-MICHEL | 2003-07-17 | — | — | US | disclosed |
| US-20030060491-A1 | Bicyclic aromatic compounds | BERNARDON JEAN-MICHEL (FR) | 2003-03-27 | — | — | US | disclosed |
| US-6515021-B1 | Bicyclic aromatic compounds | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2003-02-04 | — | — | US | disclosed |
| US-6147255-A | TOPICAL AND SYSTEMIC TREATMENT OF DERMATOLOGICAL COMPLAINTS ASSOCIATED WITH KERATINIZATION DISORDER WHICH HAS EFFECT ON DIFFERENTIATION AND ON PROLIFERATION | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060491-A1 | Bicyclic aromatic compounds | MITF, TYR, PAH | RXRA 196/4885RARG 474/4885RARB 529/4885 |
| US-20030135053-A1 | For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics | MITF, TYR, PAH | RXRA 55/4885RARG 69/4885RARB 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.